QNRX

Quoin Pharmaceuticals, Ltd.

4.38 USD

Last updated Nov 29, 11:54 UTC

Yesterday HIGH

$4.55

Yesterday LOW

$4.14

52w HIGH

$33.85

52w LOW

$3.64

EPS

-1.95

PE

-2.25

Next Earnings

Mar 6, 2024

Overview News Government Trades

Quoin Pharmaceuticals, Ltd. stock is up 3.3% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 7 November’s closed higher than October.

Quoin Pharmaceuticals, Ltd. focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Medical Equipment

Headquarters

Kfar Saba, Israel

Website

quoinpharma.com

Benzinga Newsdesk

Wed May 24, 2023

Quoin Pharmaceuticals Announces 50% Enrollment In Open Label Netherton Syndrome Clinical Trial
totan@benzinga.com

Mon May 8, 2023

Quoin Pharmaceuticals Q1 EPS $(0.34) Misses $(0.28) Estimate

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 70 percent decrease over losses of $(0.20) per share
Benzinga Insights

Mon May 8, 2023

Earnings Scheduled For May 8, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
Benzinga Insights

Fri May 5, 2023

A Preview Of Quoin Pharmaceuticals's Earnings
Lisa Levin

Tue Mar 28, 2023

Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket

Gainers Biodexa Pharmaceuticals (NASDAQ: BDRX) shares rose 76% to $0.8276 in pre-market trading after gaining 65% on Monday.
Happy Mohamed

Wed Mar 22, 2023

Watching Quoin Pharmaceuticals; Zacks Small-Cap Research Sets $4 Price Target

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_03222023_QNRX_Marin.pdf
Bill Haddad

Tue Mar 21, 2023

Quoin Pharmaceuticals Doses First Patient In Open Label Netherton Syndrome Clinical Trial
Lisa Levin

Wed Mar 15, 2023

Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Gainers
mahesh@benzinga.com

Wed Mar 8, 2023

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.
Benzinga Insights

Wed Mar 8, 2023

Earnings Scheduled For March 8, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.